

AMENDMENTS

In the claims:

Please amend the claims as follows.

Claims 1-98 (Canceled).

99. (Previously presented) An isolated peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), said peptide having a length of less than 100 residues, wherein said peptide selectively homes to tumor vasculature and selectively binds collagen.

100. (Previously presented) The isolated peptide of claim 99, which has a length of less than 50 residues.

101. (Previously presented) The isolated peptide of claim 99, which has a length of less than 20 residues.

102. (Currently amended) A conjugate comprising a therapeutic agent linked to a homing ~~molecule~~ peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), said peptide having a length of less than 100 residues, wherein said homing ~~molecule~~ peptide selectively homes to tumor vasculature and selectively binds collagen.

103. (Previously presented) The conjugate of claim 102, wherein said homing molecule selectively binds non helical collagen.

104. (Previously presented) The conjugate of claim 102, wherein said homing molecule selectively homes to breast tumor vasculature.

105. (Previously presented) The conjugate of claim 102, wherein said homing molecule selectively binds collagen IV.

106. (Previously presented) The conjugate of claim 105, wherein said homing molecule selectively binds denatured collagen IV in preference to native collagen IV.

107. (Previously presented) The conjugate of claim 105, wherein said homing molecule selectively binds the alpha 2 chain of collagen IV.

Claims 108 and 109 (Canceled).

110. (Previously presented) The conjugate of claim 102, wherein said therapeutic agent is a cancer chemotherapeutic agent.

111. (Previously presented) The conjugate of claim 102, wherein said therapeutic agent is a cytotoxic agent.

112. (Previously presented) The conjugate of claim 102, wherein said therapeutic agent is an anti-angiogenic agent.

113. (Previously presented) The conjugate of claim 102, wherein said therapeutic agent is a polypeptide.

114. (Withdrawn) The conjugate of claim 102, wherein said therapeutic agent is a nucleic acid molecule.

115. (Withdrawn) The conjugate of claim 102, wherein said therapeutic agent is a small molecule.

116. (Withdrawn) The conjugate of claim 102, which comprises a virus.

117. (Withdrawn) The conjugate of claim 116, which comprises a phage.

118. (Previously presented) The conjugate of claim 102, comprising at least two homing molecules that each selectively homes to tumor vasculature and selectively binds collagen.

119. (Previously presented) The conjugate of claim 118, wherein said at least two homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1), each of said at least two homing molecules having a length of less than 100 residues.

120. (Previously presented) The conjugate of claim 102, comprising at least ten homing molecules that each selectively homes to tumor vasculature and selectively binds collagen.

121. (Previously presented) The conjugate of claim 120, wherein said at least ten homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1)), each of said at least ten homing molecules having a length of less than 100 residues.

122. (Previously presented) The conjugate of claim 102, comprising at least 100 homing molecules that each selectively homes to tumor vasculature and selectively binds collagen.

123. (Previously presented) The conjugate of claim 122, wherein said at least 100 homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1)), each of said at least 100 homing molecules having a length of less than 100 residues.

124. (Withdrawn) The conjugate of claim 122, which comprises a virus.

125. (Withdrawn) The conjugate of claim 124, wherein said virus is a phage.

Claims 126-177 (Canceled).

178. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 40 residues.

179. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 35 residues.

180. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 30 residues.

181. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 25 residues.

182. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 15 residues.

183. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 10 residues.

184. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 9 residues.

185. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 8 residues.

186. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 7 residues.

187. (Previously presented) The isolated peptide of claim 99, said peptide having a length of less than 6 residues.

188. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 50 residues.

189. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 40 residues.

190. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 35 residues.

191. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 30 residues.

192. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 25 residues.

193. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 20 residues.

194. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 15 residues.

195. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 10 residues.

196. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 9 residues.

197. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 8 residues.

198. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 7 residues.

199. (Previously presented) The conjugate of claim 102, wherein the peptide portion of said conjugate has a length of less than 6 residues.